You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

ID: GL-C50-01 Jan 2011
Type of Content: Guidelines & Advice, Health System
Document Status: Current
Expert Panel

Guideline Objective

Cancer Care Ontario struck the Ontario Neuroendocrine Expert Panel to develop recommendations for the organization and delivery of radionuclide (RN) therapy for NET patients in Ontario. The work was supported by Cancer Care Ontario’s Program in Evidence-Based Care (PEBC) division, who performed a formal search for evidence to support these guidelines, and for existing guidelines in other jurisdictions. Data sources available to Cancer Care Ontario were also used to provide information on current patterns of care.

Intended Guideline Users

Physicians and Health Care Administrators